GW Pharmaceuticals PLC- Target of Unusually High Options Trading (GWPH)

GW Pharmaceuticals PLC- (NASDAQ:GWPH) saw some unusual options trading activity on Tuesday. Investors purchased 2,364 put options on the stock. This is an increase of 1,466% compared to the typical volume of 151 put options.

Shares of GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $126.90 on Friday. The company has a current ratio of 11.44, a quick ratio of 7.47 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $143.37. The firm has a market cap of $3,220.00, a price-to-earnings ratio of -14.31 and a beta of 2.50.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. The business had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $2.18 million. analysts anticipate that GW Pharmaceuticals PLC- will post -7.76 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its position in GW Pharmaceuticals PLC- by 23.2% during the 4th quarter. Wells Fargo & Company MN now owns 24,185 shares of the biopharmaceutical company’s stock worth $3,192,000 after purchasing an additional 4,549 shares during the period. Granite Point Capital Management L.P. purchased a new stake in GW Pharmaceuticals PLC- during the 4th quarter worth $5,280,000. AGF Investments Inc. purchased a new position in GW Pharmaceuticals PLC- in the 4th quarter valued at about $1,345,000. Sigma Planning Corp purchased a new position in GW Pharmaceuticals PLC- in the 4th quarter valued at about $249,000. Finally, California Public Employees Retirement System purchased a new position in GW Pharmaceuticals PLC- in the 4th quarter valued at about $6,601,000. 74.49% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently issued reports on the stock. Bank of America lowered their price objective on shares of GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating for the company in a research note on Tuesday. Leerink Swann boosted their price objective on shares of GW Pharmaceuticals PLC- from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $192.00 price target (down from $208.00) on shares of GW Pharmaceuticals PLC- in a research report on Monday. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Finally, BidaskClub cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $146.38.

COPYRIGHT VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://sportsperspectives.com/2018/02/09/gw-pharmaceuticals-plc-target-of-unusually-high-options-trading-gwph.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply